DFTX
Definium Therapeutics, Inc.
$44.48
+0.15 (+0.34%)
At close · Jul 7
Market Cap
$5.09B
Shares
109,066,783
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$44.48
Open$44.35
Day$42.50–45.38
52W$6.95–49.20
Avg vol 30d3.9M
Short int10.6M · 9.8% float · 4.4d
Short vol50%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+145%
above
Price vs 50-day avg
+64%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+89%
trailing
6-month return
+220%
trailing
YTD return
+232%
this year
Relative strength
+213%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
5 of 249 funds reported for Jun 30 · net +27.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.75% of float · ▲ +12.8% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
249 holders — 13F breadth
Squeeze score
64
elevated · 0–100
Fundamentals
EPS growth
−34%
Y/Y
Balance sheet
$257.8M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+145%
Bullish
Price vs 50-day avg
+64%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $27 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
5 of 249 funds reported for Jun 30 · net +27.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.75% of float · ▲ +12.8% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
249 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $7
Now $44 · 89%
52-wk high $49
vs 200-day avg +145%
vs 50-day avg +64%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DFTX
this stock
Definium Therapeutics, Inc.
|
$5.09B | +232.2% | — | — | 9.8% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DFTX | -4.5% | +88.9% | +220.5% | -5.4% | +232.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -5.4% | +87.5% | +212.9% | -5.6% | +222.5% |